Ann Hepatobiliary Pancreat Surg.  2021 May;25(2):179-191. 10.14701/ahbps.2021.25.2.179.

Advances in neoadjuvant therapy for resectable pancreatic cancer over the past two decades

Affiliations
  • 1Department of General and Digestive Surgery, Hospital General Universitario Gregorio Marañon, Complutense University of Madrid, Madrid, Spain
  • 2Transplant and Hepatobiliopancreatic Surgery Unit, Department of General and Digestive Surgery, Hospital General Universitario Gregorio Marañón, Madrid, Spain
  • 3Departments of Medical Oncology, Department of Oncology, Hospital general Universitario Gregorio Marañon, Complutense University of Madrid, Madrid, Spain
  • 4Departments of Radiation Oncology, Department of Oncology, Hospital general Universitario Gregorio Marañon, Complutense University of Madrid, Madrid, Spain

Abstract

In the last two decades, pancreatic cancer has been undergoing important changes in its perioperative management due to the great interest in multidisciplinary management and preoperative multimodal therapy, which in numerous studies have shown promising clinical results. Although the standard of treatment for resectable pancreatic ductal adenocarcinoma (PDAC) today is surgery followed by adjuvant therapy, as it is a biologically aggressive disease, even with complete resection, it has high rates of local and distant relapse. Several retrospective and prospective phase I/II studies have opened the window for neoadjuvant therapy with chemotherapy (CT), chemoradiotherapy (CRT), or both, as an alternative treatment for resectable pancreatic cancer, with promising results. Neoadjuvant therapy could has some advantages, including early administration of systemic treatment, in vivo assessment of response to treatment, increase resectability rate in borderline patients, increase resection rate with negative margin and survival benefit. While it seems clear that even potentially resectable disease would benefit from preoperative multimodal therapy, the optimal neoadjuvant therapeutic strategy is still controversial and currently there are only recommendations for neoadjuvant treatment, in clinical guidelines such as the NCCN and ESMO, for borderline and/or locally advanced PDAC. This review provides an overview of recent studies available and how they relate to systemic treatment of resectable PDAC in the neoadjuvant setting.

Keyword

Resectable disease; Pancreatic ductal adenocarcinoma; Neoadjuvant therapy; Chemotherapy; Chemoradiotherapy

Reference

1. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. 2014; Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 74:2913–2921. DOI: 10.1158/0008-5472.CAN-14-0155. PMID: 24840647.
Article
2. Griffin JF, Smalley SR, Jewell W, Paradelo JC, Reymond RD, Hassanein RE, et al. 1990; Patterns of failure after curative resection of pancreatic carcinoma. Cancer. 66:56–61. DOI: 10.1002/1097-0142(19900701)66:1<56::AID-CNCR2820660112>3.0.CO;2-6.
Article
3. Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, et al. 2000; Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 4:567–579. DOI: 10.1016/S1091-255X(00)80105-5.
Article
4. Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Goéré D, et al. 2015; Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 26 Suppl 5:v56–v68. DOI: 10.1093/annonc/mdv295. PMID: 26314780.
Article
5. Kalser MH, Ellenberg SS. 1985; Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 120:899–903. DOI: 10.1001/archsurg.1985.01390320023003. PMID: 4015380.
6. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. 2004; A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 350:1200–1210. DOI: 10.1056/NEJMoa032295. PMID: 15028824.
Article
7. Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, et al. 2013; Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 310:1473–1481. DOI: 10.1001/jama.2013.279201. PMID: 24104372.
8. Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, et al. 2017; Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 389:1011–1024. DOI: 10.1016/S0140-6736(16)32409-6.
Article
9. Conroy T, Hammel P, Hebbar M, Abdelghani MB, Wei AC, Raoul JL, et al. 2018; Unicancer GI PRODIGE 24/CCTG PA.6 trial: a multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas. J Clin Oncol. 36(18 Suppl):LBA4001. DOI: 10.1200/JCO.2018.36.18_suppl.LBA4001.
Article
10. Labori KJ, Katz MH, Tzeng CW, Bjørnbeth BA, Cvancarova M, Edwin B, et al. 2016; Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma- a population-based cohort study. Acta Oncol. 55:265–277. DOI: 10.3109/0284186X.2015.1068445. PMID: 26213211.
11. Tzeng CW, Tran Cao HS, Lee JE, Pisters PW, Varadhachary GR, Wolff RA, et al. 2014; Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival. J Gastrointest Surg. 18:16–24. discussion 24–25. DOI: 10.1007/s11605-013-2412-1. PMID: 24241967.
Article
12. Syed AR, Carleton NM, Horne Z, Dhawan A, Bedi G, Kochhar G, et al. 2020; Survival Trends for resectable pancreatic cancer using a multidisciplinary conference: the impact of post-operative chemotherapy. J Gastrointest Cancer. 51:836–843. DOI: 10.1007/s12029-019-00303-z. PMID: 31605289.
Article
13. Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, et al. 2010; Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 304:1073–1081. DOI: 10.1001/jama.2010.1275. PMID: 20823433.
14. Lim KH, Chung E, Khan A, Cao D, Linehan D, Ben-Josef E, et al. 2012; Neoadjuvant therapy of pancreatic cancer: the emerging paradigm? Oncologist. 17:192–200. DOI: 10.1634/theoncologist.2011-0268. PMID: 22250057. PMCID: PMC3286168.
Article
15. Tienhoven GV, Versteijne E, Suker M, Groothuis KBC, Busch OR, Bonsing BA, et al. 2018; Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1): a randomized, controlled, multicenter phase III trial. J Clin Oncol. 36(18 Suppl):LBA4002. DOI: 10.1200/JCO.2018.36.18_suppl.LBA4002.
16. Lutz MP, Zalcberg JR, Ducreux M, Aust D, Bruno MJ, Büchler MW, et al. 2017; Gallen EORTC Gastrointestinal Cancer Conference: consensus recommendations on controversial issues in the primary treatment of pancreatic cancer. Eur J Cancer. 79:41–49. DOI: 10.1016/j.ejca.2017.03.022. PMID: 28460245.
17. Chun YS, Pawlik TM, Vauthey JN. 2018; 8th Edition of the AJCC cancer staging manual: pancreas and hepatobiliary cancers. Ann Surg Oncol. 25:845–847. DOI: 10.1245/s10434-017-6025-x. PMID: 28752469.
Article
18. Evans DB, George B, Tsai S. 2015; Non-metastatic pancreatic cancer: resectable, borderline resectable, and locally advanced-definitions of increasing importance for the optimal delivery of multimodality therapy. Ann Surg Oncol. 22:3409–3413. DOI: 10.1245/s10434-015-4649-2. PMID: 26122369.
Article
19. Christians KK. Tsai S, Ritch P, Erickson B, Evans D, editors. 2019. New classification of locally advanced pancreatic cancer. Management of localized pancreatic cancer. Springer;Cham: p. 97–103. DOI: 10.1007/978-3-319-98944-0_9.
Article
20. National Comprehensive Cancer Network (NCCN). 2019. NCCN clinical practice guidelines in oncology- pancreatic adenocarcinoma version 1 [Internet]. Plymouth Meeting: NCCN. Available from: https://www.nccn.org/professionals/physician_gls/pdf/pancreatic_blocks.pdf. cited 2020 Mar 20.
21. Callery MP, Chang KJ, Fishman EK, Talamonti MS, William Traverso L, Linehan DC. 2009; Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol. 16:1727–1733. DOI: 10.1245/s10434-009-0408-6. PMID: 19396496.
Article
22. Katz MH, Pisters PW, Evans DB, Sun CC, Lee JE, Fleming JB, et al. 2008; Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg. 206:833–846. discussion 846–848. DOI: 10.1016/j.jamcollsurg.2007.12.020. PMID: 18471707. PMCID: PMC5901743.
Article
23. Vauthey JN, Dixon E. 2009; AHPBA/SSO/SSAT Consensus Conference on Resectable and Borderline Resectable Pancreatic Cancer: rationale and overview of the conference. Ann Surg Oncol. 16:1725–1726. DOI: 10.1245/s10434-009-0409-5. PMID: 19396495.
Article
24. Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP, Konski A, et al. 2008; Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA. 299:1019–1026. DOI: 10.1001/jama.299.9.1019. PMID: 18319412.
25. Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, et al. 2010; Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 304:1073–1081. DOI: 10.1001/jama.2010.1275. PMID: 20823433.
26. Gnerlich JL, Luka SR, Deshpande AD, Dubray BJ, Weir JS, Carpenter DH, et al. 2012; Microscopic margins and patterns of treatment failure in resected pancreatic adenocarcinoma. Arch Surg. 147:753–760. DOI: 10.1001/archsurg.2012.1126. PMID: 22911074.
Article
27. Sohal DP, Walsh RM, Ramanathan RK, Khorana AA. 2014; Pancreatic adenocarcinoma: treating a systemic disease with systemic therapy. J Natl Cancer Inst. 106:dju011. DOI: 10.1093/jnci/dju011. PMID: 24563516.
Article
28. Khorana AA, Mangu PB, Berlin J, Engebretson A, Hong TS, Maitra A, et al. 2017; Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline update. J Clin Oncol. 35:2324–2328. DOI: 10.1200/JCO.2017.72.4948. PMID: 28398845.
Article
29. Wu W, He J, Cameron JL, Makary M, Soares K, Ahuja N, et al. 2014; The impact of postoperative complications on the administration of adjuvant therapy following pancreaticoduodenectomy for adenocarcinoma. Ann Surg Oncol. 21:2873–2881. DOI: 10.1245/s10434-014-3722-6. PMID: 24770680. PMCID: PMC4454347.
Article
30. Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, et al. 2018; FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 379:2395–2406. DOI: 10.1056/NEJMoa1809775. PMID: 30575490.
Article
31. Ohigashi H, Ishikawa O, Eguchi H, Takahashi H, Gotoh K, Yamada T, et al. 2009; Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer. Ann Surg. 250:88–95. DOI: 10.1097/SLA.0b013e3181ad65cc. PMID: 19561477.
Article
32. Heinrich S, Schäfer M, Weber A, Hany TF, Bhure U, Pestalozzi BC, et al. 2008; Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial. Ann Surg. 248:1014–1022. DOI: 10.1097/SLA.0b013e318190a6da. PMID: 19092346.
33. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. 2007; Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 297:267–277. DOI: 10.1001/jama.297.3.267. PMID: 17227978.
34. Versteijne E, Suker M, Groothuis K, Akkermans-Vogelaar JM, Besselink MG, Bonsing BA, et al. 2020; Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC trial. J Clin Oncol. 38:1763–1773. DOI: 10.1200/JCO.19.02274. PMID: 32105518.
35. van der Gaag NA, Rauws EA, van Eijck CH, Bruno MJ, van der Harst E, Kubben FJ, et al. 2010; Preoperative biliary drainage for cancer of the head of the pancreas. N Engl J Med. 362:129–137. DOI: 10.1056/NEJMoa0903230. PMID: 20071702.
Article
36. Dhir M, Malhotra GK, Sohal DPS, Hein NA, Smith LM, O'Reilly EM, et al. 2017; Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients. World J Surg Oncol. 15:183. DOI: 10.1186/s12957-017-1240-2. PMID: 29017581. PMCID: PMC5634869.
Article
37. Haeberle L, Esposito I. 2019; Pathology of pancreatic cancer. Transl Gastroenterol Hepatol. 4:50. DOI: 10.21037/tgh.2019.06.02. PMID: 31304427. PMCID: PMC6624347.
Article
38. Quiros RM, Brown KM, Hoffman JP. 2007; Neoadjuvant therapy in pancreatic cancer. Cancer Invest. 25:267–273. DOI: 10.1080/07357900701206356. PMID: 17612937.
Article
39. Evans DB, Rich TA, Byrd DR, Cleary KR, Connelly JH, Levin B, et al. 1992; Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg. 127:1335–1339. DOI: 10.1001/archsurg.1992.01420110083017. PMID: 1359851.
Article
40. Pisters PW, Abbruzzese JL, Janjan NA, Cleary KR, Charnsangavej C, Goswitz MS, et al. 1998; Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. J Clin Oncol. 16:3843–3850. DOI: 10.1200/JCO.1998.16.12.3843. PMID: 9850029.
Article
41. Calvo FA, Matute R, García-Sabrido JL, Gómez-Espí M, Martínez NE, Lozano MA, et al. 2004; Neoadjuvant chemoradiation with tegafur in cancer of the pancreas: initial analysis of clinical tolerance and outcome. Am J Clin Oncol. 27:343–349. DOI: 10.1097/01.COC.0000071462.12769.35. PMID: 15289726.
42. Hoffman JP, Lipsitz S, Pisansky T, Weese JL, Solin L, Benson AB 3rd. 1998; Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group Study. J Clin Oncol. 16:317–323. DOI: 10.1200/JCO.1998.16.1.317. PMID: 9440759.
Article
43. Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PW, et al. 2008; Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 26:3496–3502. DOI: 10.1200/JCO.2007.15.8634. PMID: 18640930.
Article
44. Varadhachary GR, Wolff RA, Crane CH, Sun CC, Lee JE, Pisters PW, et al. 2008; Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 26:3487–3495. DOI: 10.1200/JCO.2007.15.8642. PMID: 18640929.
Article
45. Christians KK, Heimler JW, George B, Ritch PS, Erickson BA, Johnston F, et al. 2016; Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy. Surgery. 159:893–900. DOI: 10.1016/j.surg.2015.09.018. PMID: 26602840.
Article
46. Winter JM, Brennan MF, Tang LH, D'Angelica MI, Dematteo RP, Fong Y, et al. 2012; Survival after resection of pancreatic adenocarcinoma: results from a single institution over three decades. Ann Surg Oncol. 19:169–175. DOI: 10.1245/s10434-011-1900-3. PMID: 21761104.
Article
47. Pisters PW, Wolff RA, Janjan NA, Cleary KR, Charnsangavej C, Crane CN, et al. 2002; Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rates, and event-free outcome. J Clin Oncol. 20:2537–2544. DOI: 10.1200/JCO.2002.11.064. PMID: 12011133.
48. Talamonti MS, Small W Jr, Mulcahy MF, Wayne JD, Attaluri V, Colletti LM, et al. 2006; A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol. 13:150–158. DOI: 10.1245/ASO.2006.03.039. PMID: 16418882.
Article
49. Palmer DH, Stocken DD, Hewitt H, Markham CE, Hassan AB, Johnson PJ, et al. 2007; A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin. Ann Surg Oncol. 14:2088–2096. DOI: 10.1245/s10434-007-9384-x. PMID: 17453298.
Article
50. Heinrich S, Pestalozzi BC, Schäfer M, Weber A, Bauerfeind P, Knuth A, et al. 2008; Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 26:2526–2531. DOI: 10.1200/JCO.2007.15.5556. PMID: 18487569.
Article
51. O'Reilly EM, Perelshteyn A, Jarnagin WR, Schattner M, Gerdes H, Capanu M, et al. 2014; A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma. Ann Surg. 260:142–148. DOI: 10.1097/SLA.0000000000000251. PMID: 24901360. PMCID: PMC4520299.
52. Casadei R, Di Marco M, Ricci C, Santini D, Serra C, Calculli L, et al. 2015; Neoadjuvant chemoradiotherapy and surgery versus surgery alone in resectable pancreatic cancer: a single-center prospective, randomized, controlled trial which failed to achieve accrual targets. J Gastrointest Surg. 19:1802–1812. DOI: 10.1007/s11605-015-2890-4. PMID: 26224039.
Article
53. Golcher H, Brunner TB, Witzigmann H, Marti L, Bechstein WO, Bruns C, et al. 2015; Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial. Strahlenther Onkol. 191:7–16. DOI: 10.1007/s00066-014-0737-7. PMID: 25252602. PMCID: PMC4289008.
54. Reni M, Balzano G, Zanon S, Zerbi A, Rimassa L, Castoldi R, et al. 2018; Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trial. Lancet Gastroenterol Hepatol. 3:413–423. DOI: 10.1016/S2468-1253(18)30081-5.
Article
55. Lutfi W, Talamonti MS, Kantor O, Wang CH, Stocker SJ, Bentrem DJ, et al. 2017; Neoadjuvant external beam radiation is associated with no benefit in overall survival for early stage pancreatic cancer. Am J Surg. 213:521–525. DOI: 10.1016/j.amjsurg.2016.11.039. PMID: 28089341.
Article
56. Mokdad AA, Minter RM, Zhu H, Augustine MM, Porembka MR, Wang SC, et al. 2017; Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer: a propensity score matched analysis. J Clin Oncol. 35:515–522. DOI: 10.1200/JCO.2016.68.5081. PMID: 27621388.
Article
57. Cloyd JM, Chen HC, Wang X, Tzeng CD, Kim MP, Aloia TA, et al. 2019; Chemotherapy versus chemoradiation as preoperative therapy for resectable pancreatic ductal adenocarcinoma: a propensity score adjusted analysis. Pancreas. 48:216–222. DOI: 10.1097/MPA.0000000000001231. PMID: 30629022.
58. Mokdad AA, Minter RM, Yopp AC, Porembka MR, Wang SC, Zhu H, et al. 2018; Comparison of overall survival between preoperative chemotherapy and chemoradiotherapy for resectable pancreatic adenocarcinoma. J Natl Compr Canc Netw. 16:1468–1475. DOI: 10.6004/jnccn.2018.7068. PMID: 30545994.
Article
59. Xiang M, Heestand GM, Chang DT, Pollom EL. 2020; Neoadjuvant treatment strategies for resectable pancreas cancer: a propensity- matched analysis of the National Cancer Database. Radiother Oncol. 143:101–107. DOI: 10.1016/j.radonc.2020.01.007. PMID: 32044168.
60. Unno M, Motoi F, Matsuyama Y, Satoi S, Matsumoto I, Aosasa S, et al. 2019; Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP-05). J Clin Oncol. 37(4 Suppl):189. DOI: 10.1200/JCO.2019.37.4_suppl.189.
Article
61. Ettrich TJ, Berger AW, Perkhofer L, Daum S, König A, Dickhut A, et al. 2018; Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer- the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group. BMC Cancer. 18:1298. DOI: 10.1186/s12885-018-5183-y. PMID: 30594153. PMCID: PMC6311014.
Article
62. Hozaeel W, Pauligk C, Homann N, Luley K, Kraus TW, Trojan J, et al. 2015; Randomized multicenter phase II/III study with adjuvant gemcitabine versus neoadjuvant/adjuvant FOLFIRINOX in resectable pancreatic cancer: The NEPAFOX trial. J Clin Oncol. 33(15 Suppl):TPS4152. DOI: 10.1200/jco.2015.33.15_suppl.tps4152.
Article
63. Sohal D, McDonough SL, Ahmad SA, Gandhi N, Beg MS, Wang-Gillam A, et al. 2017; SWOG S1505: a randomized phase II study of perioperative mFOLFIRINOX vs. gemcitabine/nab-paclitaxel as therapy for resectable pancreatic adenocarcinom. J Clin Oncol. 35(4 Suppl):TPS508. DOI: 10.1200/JCO.2017.35.4_suppl.TPS508.
Article
64. Labori KJ, Lassen K, Hoem D, Grønbech JE, Søreide JA, Mortensen K, et al. 2017; Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) - study protocol for a national multicentre randomized controlled trial. BMC Surg. 17:94. DOI: 10.1186/s12893-017-0291-1. PMID: 28841916. PMCID: PMC6389186.
Article
65. Schwarz L, Vernerey D, Bachet JB, Tuech JJ, Portales F, Michel P, et al. 2018; Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study). BMC Cancer. 18:762. DOI: 10.1186/s12885-018-4663-4. PMID: 30041614. PMCID: PMC6057099.
Article
66. Heinrich S, Pestalozzi B, Lesurtel M, Berrevoet F, Laurent S, Delpero JR, et al. 2011; Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study). BMC Cancer. 11:346. DOI: 10.1186/1471-2407-11-346. PMID: 21831266. PMCID: PMC3176241.
Article
67. Tachezy M, Gebauer F, Petersen C, Arnold D, Trepel M, Wegscheider K, et al. 2014; Sequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinoma: NEOPA- a randomized multicenter phase III study (NCT01900327, DRKS00003893, ISRCTN82191749). BMC Cancer. 14:411. DOI: 10.1186/1471-2407-14-411. PMID: 24906700. PMCID: PMC4057592.
Article
Full Text Links
  • AHBPS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr